Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan P Werntz

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
European Urology|April 10, 2019
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015Ryan P Werntz, Scott E Eggener
Translational Andrology and Urology|February 15, 2020
Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumorsRyan P Werntz, Scott E Eggener
Current Opinion in Urology|December 13, 2017
Novel focal therapy treatment options for prostate cancerRyan P Werntz, Scott E Eggener
The Journal of Urology|August 1, 2018
Editorial CommentRyan P Werntz, Gary D Steinberg
World Journal of Urology|December 6, 2018
Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)Ryan P Werntz, Brittany Adamic, Gary D Steinberg
The Medical Clinics of North America|February 7, 2018
Testicular Cancer: Epidemiology, Diagnosis, and ManagementZachary L Smith, Ryan P Werntz, Scott E Eggener
Journal of Endourology|September 26, 2022
Bilateral Nerve-Sparing Robot-Assisted Retroperitoneal Lymph Node Dissection: A Minimally Invasive ApproachCarter J Colwell, Johnny R Lindquist, Ryan P Werntz
Current Urology Reports|November 30, 2019
Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG ShortageVignesh T Packiam, Ryan P Werntz, Gary D Steinberg
Current Opinion in Urology|July 7, 2018
Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissectionRyan P Werntz, Shane M Pearce, Scott E Eggener
The Journal of Urology|July 10, 2019
Reply by AuthorsCraig Labbate, Ryan P Werntz, Brittany Adamic, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
European Urology|April 10, 2019
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015Ryan P Werntz, Scott E Eggener
Translational Andrology and Urology|February 15, 2020
Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumorsRyan P Werntz, Scott E Eggener
Current Opinion in Urology|December 13, 2017
Novel focal therapy treatment options for prostate cancerRyan P Werntz, Scott E Eggener
The Journal of Urology|August 1, 2018
Editorial CommentRyan P Werntz, Gary D Steinberg
World Journal of Urology|December 6, 2018
Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)Ryan P Werntz, Brittany Adamic, Gary D Steinberg
The Medical Clinics of North America|February 7, 2018
Testicular Cancer: Epidemiology, Diagnosis, and ManagementZachary L Smith, Ryan P Werntz, Scott E Eggener
Journal of Endourology|September 26, 2022
Bilateral Nerve-Sparing Robot-Assisted Retroperitoneal Lymph Node Dissection: A Minimally Invasive ApproachCarter J Colwell, Johnny R Lindquist, Ryan P Werntz
Current Urology Reports|November 30, 2019
Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG ShortageVignesh T Packiam, Ryan P Werntz, Gary D Steinberg
Current Opinion in Urology|July 7, 2018
Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissectionRyan P Werntz, Shane M Pearce, Scott E Eggener
The Journal of Urology|July 10, 2019
Reply by AuthorsCraig Labbate, Ryan P Werntz, Brittany Adamic, et al.
Pageof 3